🚀 VC round data is live in beta, check it out!
Arcellx Valuation Multiples
Discover revenue and EBITDA valuation multiples for Arcellx and similar public comparables like Bachem, China Resources Sanjiu, Protagonist Therapeutics, Glenmark Pharma and more.
Arcellx Overview
About Arcellx
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Founded
2014
HQ
Employees
163
Website
Sectors
Financials (LTM)
EV
$6B
Arcellx Financials
Arcellx reported last 12-month revenue of $42M and negative EBITDA of ($244M).
In the same LTM period, Arcellx generated $39M in gross profit, ($244M) in EBITDA losses, and had net loss of ($226M).
Revenue (LTM)
Arcellx P&L
In the most recent fiscal year, Arcellx reported revenue of $28M and EBITDA of ($222M).
Arcellx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $42M | XXX | $28M | XXX | XXX | XXX |
| Gross Profit | $39M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($244M) | XXX | ($222M) | XXX | XXX | XXX |
| EBITDA Margin | (586%) | XXX | (782%) | XXX | XXX | XXX |
| EBIT Margin | (597%) | XXX | (890%) | XXX | XXX | XXX |
| Net Profit | ($226M) | XXX | ($228M) | XXX | XXX | XXX |
| Net Margin | (543%) | XXX | (804%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Arcellx Stock Performance
Arcellx has current market cap of $7B, and enterprise value of $6B.
Market Cap Evolution
Arcellx's stock price is $115.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $7B | -0.0% | XXX | XXX | XXX | $-3.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArcellx Valuation Multiples
Arcellx trades at 151.8x EV/Revenue multiple, and (25.9x) EV/EBITDA.
EV / Revenue (LTM)
Arcellx Financial Valuation Multiples
As of April 19, 2026, Arcellx has market cap of $7B and EV of $6B.
Equity research analysts estimate Arcellx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcellx has a P/E ratio of (29.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 151.8x | XXX | 222.9x | XXX | XXX | XXX |
| EV/EBITDA | (25.9x) | XXX | (28.5x) | XXX | XXX | XXX |
| EV/EBIT | (25.4x) | XXX | (25.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 161.7x | XXX | — | XXX | XXX | XXX |
| P/E | (29.7x) | XXX | (29.5x) | XXX | XXX | XXX |
| EV/FCF | (44.5x) | XXX | (40.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Arcellx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Arcellx Margins & Growth Rates
Arcellx's revenue in the last 12 month grew by 210%.
Arcellx's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.7M for the same period.
Arcellx's rule of 40 is (93%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcellx's rule of X is 251% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Arcellx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 210% | XXX | 158% | XXX | XXX | XXX |
| EBITDA Margin | (586%) | XXX | (782%) | XXX | XXX | XXX |
| EBITDA Growth | (16%) | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (93%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 251% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 304% | XXX | 415% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 387% | XXX | 571% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 969% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Arcellx Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Arcellx | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| China Resources Sanjiu | XXX | XXX | XXX | XXX | XXX | XXX |
| Protagonist Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Glenmark Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Belite Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcellx M&A Activity
Arcellx acquired XXX companies to date.
Last acquisition by Arcellx was on XXXXXXXX, XXXXX. Arcellx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Arcellx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArcellx Investment Activity
Arcellx invested in XXX companies to date.
Arcellx made its latest investment on XXXXXXXX, XXXXX. Arcellx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Arcellx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Arcellx
| When was Arcellx founded? | Arcellx was founded in 2014. |
| Where is Arcellx headquartered? | Arcellx is headquartered in United States. |
| How many employees does Arcellx have? | As of today, Arcellx has over 163 employees. |
| Who is the CEO of Arcellx? | Arcellx's CEO is Rami Elghandour. |
| Is Arcellx publicly listed? | Yes, Arcellx is a public company listed on Nasdaq. |
| What is the stock symbol of Arcellx? | Arcellx trades under ACLX ticker. |
| When did Arcellx go public? | Arcellx went public in 2022. |
| Who are competitors of Arcellx? | Arcellx main competitors are Bachem, China Resources Sanjiu, Protagonist Therapeutics, Glenmark Pharma. |
| What is the current market cap of Arcellx? | Arcellx's current market cap is $7B. |
| What is the current revenue of Arcellx? | Arcellx's last 12 months revenue is $42M. |
| What is the current revenue growth of Arcellx? | Arcellx revenue growth (NTM/LTM) is 210%. |
| What is the current EV/Revenue multiple of Arcellx? | Current revenue multiple of Arcellx is 151.8x. |
| Is Arcellx profitable? | No, Arcellx is not profitable. |
| What is the current EBITDA of Arcellx? | Arcellx has negative EBITDA and is not profitable. |
| What is Arcellx's EBITDA margin? | Arcellx's last 12 months EBITDA margin is (586%). |
| What is the current EV/EBITDA multiple of Arcellx? | Current EBITDA multiple of Arcellx is (25.9x). |
| What is the current FCF of Arcellx? | Arcellx's last 12 months FCF is ($142M). |
| What is Arcellx's FCF margin? | Arcellx's last 12 months FCF margin is (341%). |
| What is the current EV/FCF multiple of Arcellx? | Current FCF multiple of Arcellx is (44.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.